drugset

drugset / Trial / NCT00959686

Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma

NCT00959686 ↗

Phase 2 Completed 45 enrolled French Innovative Leukemia Organisation Mundipharma Pte Ltd. · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

A Phase II clinical study to determine the efficacy of single agent Bendamustine for T cell lymphoma "BENTLY".

Timeline

Start: 2009-09
Primary completion: 2011-06
Completion: 2013-02

Publications

Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, Banos A, Jaccard A, Park S, Tournilhac O, Schiano-de Collela JM, Voillat L, Joly B, Le Gouill S, Saad A, Cony-Makhoul P, Vilque JP, Sanhes L, Schmidt-Tanguy A, Bubenheim M, Houot R, Diouf M, Marolleau JP, Bene MC, Martin A, Lamy T. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol. 2013 Jan 1;31(1):104-10. doi: 10.1200/JCO.2012.43.7285. Epub 2012 Oct 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bendamustine	Small molecule	120 mg/m2	Intravenous

Indications